retatrutide new england journal of medicine An experimental drug nicknamed "Reta" produced greater weight loss than any GLP-1 currently on the market: https://bit.ly/4dQOfH7 Retatrutide: The New Triple-Agonist Weight

Those who lose weight more gradually and maintain adequate nutrition are less likely to experience significant shedding

The osteogenic effect of impact-loading and resistance exercise on bone mineral density in middle-aged and older men: a pilot study

This graduated dosing approach mirrors what we see with current GLP-1 treatments, where starting low and increasing gradually helps minimise side effects

Retatrutide differs from other weight loss medicines partly because the glucagon receptor it activates is thought to increase energy expenditure and promote fat burning in addition to the appetite-suppressing effects of GLP-1 and GIP

Skip this adaptation period, and you are fighting your own biology instead of working with it

Some surgeons recommend adjusting or temporarily pausing GLP-1 medications around the time of surgery due to considerations such as delayed gastric emptying and anesthesia safety